Vincent LoPriore Discloses 21.46% Stake in Hepion Pharmaceuticals, Inc. via Schedule 13D

On May 1, 2026, Vincent LoPriore, the Executive Chairman of Hepion Pharmaceuticals, Inc. (HEPA), filed a Schedule 13D disclosing a significant new ownership stake in the company. As of the event date on April 21, 2026, LoPriore beneficially owns 6,250,000 shares of Common Stock, representing 21.46% of the class. This position is held through multiple entities: 5,000,000 shares are held by Gravitas Capital LP, where LoPriore serves as Managing Member, and 1,250,000 shares are held by the Invictus Capital Advisors Pension Plan, for which LoPriore is the trustee and beneficiary. The aggregate purchase price for these securities was approximately $250,000. The filing indicates that the shares were acquired for investment purposes, and the reporting persons may make further acquisitions depending on market conditions. This filing marks a transition from zero reported holdings to a substantial majority position, establishing LoPriore as a primary stakeholder in the issuer. No other specific plans or proposals regarding the issuer were disclosed in the filing.